The post-aspirin bleeding time: a screening test for evaluating haemostatic disorders. 1979

M J Stuart, and M L Miller, and F R Davey, and J A Wolk

To evaluate the usefulness of the template bleeding time post-aspiring ingestion, this test was performed with other tests of haemostasis in 28 controls and 71 patients. The mean bleeding time (B.T.) in 24/28 true controls was 3.5 +/- 1 min (1 SD). Following the ingestion of 600 mg aspirin the B.T. was 6.3 +/- 1.4 min. Four out of 28 false 'controls' with negative bleeding histories were documented to have asymptomatic von Willebrand's disease and abnormal post-aspirin B.T. Of the 71 patients studied, 22 had initial B.T. that were abnormal (16 with classical von Willebrand's disease and six with platelet dysfunction). Of the remaining 49 patients with initially normal B.T., 30 had abnormal post-aspirin B.T. Of these 30 patients 13 had von Willebrand's disease. In eight, initially the abnormal B.T. post-aspirin was the only abnormality demonstrable but later they were shown to have von Willebrand's disease. In four the abnormal post-aspirin B.T. was combined with abnormal Ristocetin aggregations and a positive family history. These patients were presumed to have a variant of von Willebrand's disease. The remaining five had platelet dysfunctional states. Of the 19 patients with normal initial post-aspirin B.T., 16 demonstrated no haemostatic abnormality, and three were proven to have von Willebrand's disease. The aspirin tolerance test raised the sensitivity of the B.T. as a screening test for haemostasis from 40% to 94% in the abnormal patient population.

UI MeSH Term Description Entries
D001760 Bleeding Time Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function. Aspirin Tolerance Test,Bleeding Time, Template,Duke Method,Ivy Method,Template Bleeding Time,Aspirin Tolerance Tests,Bleeding Times,Bleeding Times, Template,Method, Duke,Method, Ivy,Template Bleeding Times,Test, Aspirin Tolerance,Tests, Aspirin Tolerance,Time, Bleeding,Time, Template Bleeding,Times, Bleeding,Times, Template Bleeding,Tolerance Test, Aspirin,Tolerance Tests, Aspirin
D001778 Blood Coagulation Disorders Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. Coagulation Disorders, Blood,Disorders, Blood Coagulation,Blood Coagulation Disorder,Coagulation Disorder, Blood,Disorder, Blood Coagulation
D001791 Blood Platelet Disorders Disorders caused by abnormalities in platelet count or function. Thrombocytopathy,Blood Platelet Disorder,Disorder, Blood Platelet,Disorders, Blood Platelet,Platelet Disorder, Blood,Platelet Disorders, Blood,Thrombocytopathies
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D001241 Aspirin The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5) Acetylsalicylic Acid,2-(Acetyloxy)benzoic Acid,Acetysal,Acylpyrin,Aloxiprimum,Colfarit,Dispril,Easprin,Ecotrin,Endosprin,Magnecyl,Micristin,Polopirin,Polopiryna,Solprin,Solupsan,Zorprin,Acid, Acetylsalicylic
D014842 von Willebrand Diseases Group of hemorrhagic disorders in which the VON WILLEBRAND FACTOR is either quantitatively or qualitatively abnormal. They are usually inherited as an autosomal dominant trait though rare kindreds are autosomal recessive. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII, and impaired platelet adhesion. Angiohemophilia,Hemophilia, Vascular,von Willebrand Disease,Vascular Pseudohemophilia,Von Willebrand Disorder,Von Willebrand's Factor Deficiency,von Willebrand Disease, Recessive Form,von Willebrand's Disease,von Willebrand's Diseases,Angiohemophilias,Disorder, Von Willebrand,Pseudohemophilia, Vascular,Pseudohemophilias, Vascular,Vascular Hemophilia,Vascular Hemophilias,Vascular Pseudohemophilias

Related Publications

M J Stuart, and M L Miller, and F R Davey, and J A Wolk
March 1986, Anesthesiology,
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
May 1985, The American journal of medicine,
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
March 1970, The New England journal of medicine,
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
November 1969, The New England journal of medicine,
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
July 1972, The New England journal of medicine,
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
November 1970, JAMA,
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
June 1979, Lancet (London, England),
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
November 1978, Lancet (London, England),
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
July 1979, Lancet (London, England),
M J Stuart, and M L Miller, and F R Davey, and J A Wolk
January 1978, Lancet (London, England),
Copied contents to your clipboard!